[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Institut universitaire de cardiologie et de pneumologie de Québec, University Laval\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":268},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,45,76,97,120,142,176,205,237],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100588589","role-of-anti-trek-1-autoantibodies-in-scvf-100588589",false,"NCT06943365","Role of Anti-TREK-1 Autoantibodies in SCVF","Circulating Anti-TREK-1 Autoantibodies as Diagnostic and Prognostic Biomarkers in Short-Coupled Ventricular Fibrillation","TRACK-VF","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of SCVF as per current criteria\n* Willingness to provide written informed consent\n\nExclusion Criteria:\n\n\\- SCVF patients \\\u003C age 18","ALL","18 Years",{"count":20,"type":21},300,"ESTIMATED","24 Months","OBSERVATIONAL","Short-coupled ventricular fibrillation (SCVF) is a lethal, primary electrical disorder and an important cause of unexplained cardiac arrest.1 Recent work from our group suggests that a substantial proportion of SCVF cases is associated to circulating autoantibodies targeting TREK-1, a cardiac potassium channel, resulting in an abnormal gain-of-function which is the prerequisite for the SCVF phenotype.2 This proposal is a translational multicenter study to validate anti-TREK-1 autoantibodies as a diagnostic and prognostic biomarker in a large, diversified cohort of SCVF patients (Figure 1). Functional, cellular experiments in patient-derived hiPSC cardiomyocytes and Purkinje cells will be performed to explore the cell type-specific role of TREK-1 in arrhythmogenesis, while single-nuclear RNA sequencing (snRNA-seq) will allow us to establish the transcriptomic profile (Figure 1). These results will identify the cellular substrate for SCVF.",[26,27],"Short-coupled Ventricular Fibrillation","Idiopathic Ventricular Fibrillation",[29,30,31],"SCVF","anti-TREK-1 antibodies","IVF","RECRUITING","2026-06-15",{"date":35,"type":36},"2026-06-16","ACTUAL",{"date":38,"type":36},"2025-05-01",{"date":40,"type":21},"2028-12-31",{"name":42,"class":43},"Institut universitaire de cardiologie et de pneumologie de Québec, University Laval","OTHER",5,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100634439","an-initial-experience-with-the-disposable-celsio-cryocatheter-system-for-diagnostic-and-interventional-bronchoscopy-100634439","NCT07539701","An Initial Experience With the Disposable Celsio Cryocatheter System for Diagnostic and Interventional Bronchoscopy","CELSIO","Inclusion Criteria:\n\n\\- Patient undergoing a bronchoscopic procedure with planned use of a 1.7mm cryocatheter\n\nExclusion Criteria:\n\n* Patient undergoing a bronchoscopic procedure with planned use of a different size cryocatheter (eg 1.1 or 2.4mm)\n* Current pregnancy or lactation\n* Lack of free and informed consent",{"count":53,"type":21},30,"INTERVENTIONAL",[56],"NA","This clinical trial is intended for patients awaiting an interventional bronchoscopy procedure where the use of a cryocatheter is considered. This type of catheter is already used in clinical practice for the treatment of certain types of bronchial obstructions, including tumors, granulomas, and for foreign bodies extractions. This catheter uses extremely cold temperatures offering unique advantages compared to heat-based technologies. Different types of reusable and single-use cryocatheters are actually available on the market. This type of device requires the use of expensive and bulky consoles operating with heavy gas tanks, resulting in high maintenance costs. A Quebec, Canada based company has developed a cryocatheter that combines procedural efficacy with practical considerations in mind. The Celsio cryocatheter operates without a console and is designed to accommodate the bronchscopist through the different types of cryogenic procedures.\n\nThis study aims to generate meaningful, real-world evidence without interfering with standard clinical care. The collected data will serve to characterize the device's performance profile, identify best practices for its use, and provide data for the design of future prospective comparative studies.",[59,60],"Lung Cancer (Diagnosis)","Interstitial Lung Disease (ILD)",[62,63,64,65],"cryocathter","cryobiopsy","cryo-extraction","cryodevitalization","NOT_YET_RECRUITING","2026-04-13",{"date":69,"type":36},"2026-04-20",{"date":71,"type":21},"2026-03-23",{"date":73,"type":21},"2028-03-23",{"name":42,"class":43},1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":75},"100548425","valve-performance-of-the-sapien-3-ultra-resilia-valve-a-prospective-registry-with-central-echocardiography-analysis-100548425","NCT06420830","Valve Performance of the SAPIEN 3 Ultra RESILIA Valve: A Prospective Registry With Central Echocardiography Analysis.","Title Valve Performance of the SAPIEN 3 Ultra RESILIA Valve: A Prospective Registry With Central Echocardiography Analysis.","Inclusion Criteria:\n\n* Inclusion criteria - Patients with severe aortic stenosis undergoing transarterial TAVR with the SAPIEN 3 Ultra RESILIA valve.\n* Successful valve implantation of the SAPIEN 3 Ultra RESILIA valve.\n\nVARC-3- defined technical success defined as:\n\n* Freedom from mortality\n* Successful access, delivery of the device, and retrieval of the delivery system\n* Correct positioning of a single prosthetic heart valve into the proper anatomical location\n* Freedom from surgery or intervention related to the device (excluding permanent pacemaker) or to a major vascular or access related, or cardiac structural complication - Absence of severe procedural or in-hospital complications (VARC-3 definitions): mortality, stroke, bleeding type 2-4, myocardial infarction, need for a second valve, valve embolization, coronary obstruction, annular rupture.\n\nExclusion Criteria:\n\n* Age \\>80 years\n* Severe pulmonary disease (FEV1 \\\u003C50% predicted or need for home oxygen)\n* Severe renal dysfunction (eGFR \\\u003C30 ml\u002Fmin\u002F1.73m2)\n* Frailty (Clinical Frailty Scale \\> 4)\n* Severe coronary disease (SYNTAX score \\>32)\n* Left ventricular ejection fraction ≤30%\n* Moderate-to-severe mitral regurgitation\n* Severe tricuspid regurgitation\n* Pulmonary systolic pressure \\>60 mmHg\n* STS-PROM \\>5%\n* Any disease leading to a life expectancy \\\u003C5 years","80 Years",{"count":85,"type":21},150,"The issue of valve durability has become one of the most important aspects in the TAVR field in recent years since transcatheter aortic valve replacement has been progressively applied to younger patients with a low co-morbidity burden. The SAPIEN 3 Ultra RESILIA valve represents the last generation of the SAPIEN valve system and includes several important iterations (newer leaflet calcium-blocking technology targeting calcium-attracting free aldehydes, dry tissue storage, newer skirt textile design) that should translate into a favorable impact on valve durability at mid- to long- term follow-up",[88,89],"Aortic Valve Stenosis","Transcatheter Aortic Valve Replacement",{"date":91,"type":36},"2026-03-27",{"date":93,"type":36},"2024-05-16",{"date":95,"type":21},"2034-09-01",{"name":42,"class":43},{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":75},"100529740","recurrent-or-persistent-device-related-thrombus-after-left-atrial-appendage-occlusion-the-re-drt-study-100529740","NCT06177704","Recurrent or Persistent Device Related Thrombus After Left Atrial Appendage Occlusion: The RE-DRT Study","RE-DRT","Inclusion Criteria:\n\n* Patients with diagnosis of probable\u002Fdefinite DRT after LAAO detected by transesophageal echocardiography (TEE) or cardiac computed tomography (CT).\n* Age≥18 years old.\n\nExclusion Criteria:\n\n* Unable to provide informed consent",{"count":105,"type":21},100,"This study is a prospective, multicenter international trial aimed at assessing the actual incidence, identifying associated factors, and evaluating the clinical consequences of both persistent and recurrent device-related thrombus (DRT) following percutaneous left atrial appendage occlusion (LAAO).\n\nWhile LAAO has shown efficacy in reducing the risk of stroke, device-related thrombus (DRT) remains a significant concern. The reported incidence of DRT varies, and it is associated with an elevated risk of ischemic stroke and death. The study highlights that persistent and recurrent DRT pose higher risks of thromboembolic events, and current data come from retrospective studies with non-standardized imaging follow-up protocols. The timing of imaging follow-up is crucial, and the study notes discrepancies in recommendations from expert statements. The EHRA\u002FEAPCI suggests imaging at specific intervals post-procedure, while the SCAI\u002FHRS recommends repeat imaging at shorter intervals to assess DRT resolution. The study underscores the need for dedicated prospective data to accurately determine the incidence, factors, and clinical impact of persistent and recurrent DRT after LAAO.",[108,109,110,111,112],"Percutaneous Left Atrial Appendage Occlusion (LAAO)","Device-related Thrombus (DRT)","Thromboembolic Event","Major Cardioembolic Events","Major Bleeding - TIMI Classification",{"date":114,"type":36},"2026-03-24",{"date":116,"type":21},"2026-12-01",{"date":118,"type":21},"2028-01-01",{"name":42,"class":43},{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":54,"phases":130,"briefSummary":131,"conditions":132,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":135,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":141},"100474540","valve-hemodynamic-optimization-based-on-doppler-echocardiography-vs-catheterization-measurements-following-viv-tavr-100474540","NCT05459233","Valve Hemodynamic Optimization Based on Doppler-Echocardiography vs Catheterization Measurements Following ViV TAVR","Valve Hemodynamic Optimization Based on Doppler-Echocardiography Versus Catheterization Measurements Following Valve-in-Valve TAVR: A Prospective Randomized Trial","ECHOCATH","Inclusion Criteria:\n\n* Patients with surgical aortic bioprosthetic valve failure defined as severe aortic stenosis and\u002For regurgitation approved for a valve-in-valve procedure by the Heart Team\n* Surgical stented bioprosthetic valve (label size ≤25 mm)\n* TAVR with the SAPIEN 3 Ultra valve\n\nExclusion Criteria:\n\n* Stentless or sutureless surgical valves\n* Trifecta bioprosthesis\n* Hancock II bioprosthesis\n* High-risk of coronary obstruction (defined either as a virtual transcatheter valve - coronary distance as evaluated by CT \\\u003C4 mm or based on the criterion of the heart team responsible for the procedure).\n* Impossibility to obtain written informed consent",{"count":129,"type":21},310,[56],"Data on valve performance following ViV-TAVR has usually been obtained with the use of Doppler-echocardiography. However, some reports have shown significant discordances in the evaluation of mean transvalvular gradient between echocardiography and catheterization, with an overestimation of the real gradient with echo (vs. cath) in most cases. Thus, the incidence of procedural-device failure may be lower than that reported in the ViV-TAVR literature,",[88,133,134],"Aortic Valve Regurgitation","Prosthesis Failure",{"date":114,"type":36},{"date":137,"type":36},"2023-01-11",{"date":139,"type":21},"2029-09-01",{"name":42,"class":43},7,{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":149,"targetDuration":151,"studyType":23,"phases":4,"briefSummary":152,"conditions":153,"keywords":157,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":75},"100629279","obesity-medicine-bank-of-the-quebec-heart-and-lung-institute---laval-university-iucpq-ulaval-100629279","NCT07472608","Obesity Medicine Bank of the Quebec Heart and Lung Institute - Laval University (IUCPQ-ULaval)","Database and Biological Material Bank in Obesity Medicine of the Quebec Heart and Lung Institute - Laval University (IUCPQ-ULaval)","To be included in the registry (database + biobank), a person must first be referred to the Bariatric Medicine Clinic at the IUCPQ-ULaval and meet several criteria:\n\n1. Be over 18 years of age\n2. Meet at least one of the following five criteria:\n\n   1. Body mass index ≥30 kg\u002Fm2 with or without comorbidities (preclinical or clinical obesity);\n   2. Require weight loss related to a transplant, bariatric surgery, or another type of surgery (e.g., hernia repair, orthopedic surgery, neurosurgery, etc.);\n   3. History of bariatric surgery resulting in weight regain of at least 15% of the total weight lost;\n   4. History of bariatric surgery resulting in weight loss deemed insufficient by the treating medical team;\n   5. Having undergone bariatric surgery with complications related to it (i.e., flushing syndrome or hypoglycemia, nephrolithiasis, return of comorbidities in remission, abnormalities in phosphocalcic balance and vitamin deficiencies).",{"count":150,"type":21},25000,"25 Years","Obesity medicine, or bariatric medicine, focuses not only on the biological and behavioral aspects, but also on the environmental and social factors that contribute to the development of obesity. Many diseases are associated with obesity, such as type 2 diabetes, hypertension, cardiovascular diseases, numerous cancers, gynecological disorders, etc. Focusing on obesity medicine is crucial for improving patients' quality of life, reducing healthcare costs, and developing effective prevention strategies. The Quebec Heart and Lung Institute - Laval University (IUCPQ-ULaval) maintains a clinical database and biological material bank for studying the multidisciplinary management of obesity and its complications.\n\nA biobank is a collection of information, clinical or biochemical data (including radiological, cardiac, and genetic data), and blood samples concerning donors. The information that can be collected includes, for example, age, sex, diagnosis, progression or treatment of a medical condition, medications, DNA, etc. DNA is a molecule present in all cells and contains all the information necessary for the development and functioning of our body.\n\nThis bank aims to better characterize patients' profile receiving follow-up care in obesity medicine, identify predictive factors of success or failure of interventions and adapt management strategies according to specific needs. The collected data and blood samples will be used in several research projects with the following objectives:\n\n1. To document the socioeconomic, demographic, clinical, radiological, genetic, and biochemical characteristics of patients living with obesity and requiring medical follow-up at the bariatric medicine clinic at the IUCPQ-ULaval\n2. To explore the effects or associations of genetic and biochemical determinants on health in the context of obesity\n3. To gain a better understanding of the pathophysiology and genes involved in obesity and associated metabolic abnormalities\n4. To evaluate the clinical utility of non-invasive biomarkers in the screening of preclinical obesity and its comorbidities and\u002For\n5. To evaluate the effectiveness of medications, health behavior changes, and bariatric surgery in order to develop optimal interventions aimed at improving the health and medical management of people with obesity.",[154,155,156],"Obesity","Metabolic Abnormalities","Health",[158,159,160,161,162,163,164,165,166,156,167],"Biobank","Clinical data","Radiological data","Genetic data","Biochemical data","Cardiac data","Blood samples","Prospective patient registry","Bariatric medicine","Obesity medicine","2026-03-11",{"date":170,"type":36},"2026-03-16",{"date":172,"type":21},"2026-06-01",{"date":174,"type":21},"2051-06",{"name":42,"class":43},{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":54,"phases":186,"briefSummary":187,"conditions":188,"keywords":191,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":75},"100589138","general-anesthesia-vs-conscious-sedation-for-radial-endobronchial-ultrasound-100589138","NCT06950515","General Anesthesia vs Conscious Sedation for Radial Endobronchial Ultrasound","A Randomized Controlled Trial of gEneral aneStheSia vs consciOUs Sedation in Radial endobronChial Ultrasound for Peripheral Pulmonary lEsions","RESSOURCE","Inclusion Criteria:\n\n* Age ≥ 18 years and ability to consent\n* Peripheral lung lesion less than 5cm in average diameter on axial CT images (A lung lesion will be considered peripheral if it is located beyond the origin of the subsegmental bronchi and presumed not to be visible endoscopically in white light during the evaluation of the CT scan by an interventional pulmonologist.)\n* Lesion deemed accessible by pEBUS by an experienced interventional pulmonologist\n* Decision by the medical team and the patient to use pEBUS as a diagnostic modality for the lung lesion\n\nExclusion Criteria:\n\n* Planned use of electromagnetic navigation, augmented fluoroscopy or robotic bronchoscopy in addition to pEBUS. The use of virtual bronchoscopy planning is permitted\n* Presence of suspicious lymph nodes (size ≥ 10mm and\u002For moderate or greater hypermetabolism) on imaging which are accessible by l-EBUS and for which rapid on-site cytological analysis will be used\n* Contraindication to bronchoscopy or biopsies such as an unstable medical condition or uncorrected coagulopathy\n* Current pregnancy\n* Lack of free and informed consent",{"count":185,"type":21},306,[56],"The endoscopic investigation of lung lesions is experiencing significant growth with the increasing number of lung cancer screening programs. Peripheral endobronchial ultrasound (pEBUS) is the most widely used endoscopic technique in the investigation of peripheral pulmonary lesions (PPL). It is performed in relatively equal proportions under conscious sedation and general anesthesia by interventional pulmonologists throughout the world. Users of conscious sedation justify themselves by the fewer resources consumed and the absence of demonstration of a superior diagnostic yield of general anesthesia while users of general anesthesia claim diagnostic yield and comfort for the patient are superior with their approach. Our main objective is to compare the diagnostic yield of pEBUS under general anesthesia to that obtained under conscious sedation.",[189,190],"Lung Cancers","Peripheral Pulmonary Nodules",[192,193,194,195,196],"Lung cancer","Peripheral pulmonary nodules","bronchoscopy","peripheral endobronchial ultrasound","sedation","2026-03-04",{"date":199,"type":36},"2026-03-06",{"date":201,"type":36},"2025-09-25",{"date":203,"type":21},"2029-08",{"name":42,"class":43},{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":213,"targetDuration":4,"studyType":54,"phases":215,"briefSummary":216,"conditions":217,"keywords":220,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":75},"100574805","characterization-and-management-of-metabolic-dysfunction-associated-fatty-liver-disease-mafld-100574805","NCT06764056","Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)","Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Through an Individualized Nutritionnal Approach and Semaglutide Therapy.","METAfoie","Inclusion Criteria:\n\n* Body mass index between 30 and 50 kg\u002Fm2;\n* Stade 2 or 3 (S2 or S3) hepatic steatosis with or without liver fibrosis.\n\nExclusion Criteria:\n\n* Type 1 diabetes diagnosis;\n* Alcohol consumption exceeding recommendations \\[\\>140 g\u002Fweek (women) and \\>210 g\u002Fweek (men)\\];\n* Known chronic hepatic disease non-steatotic at the entry of the study (Wilson's disease, hemochromatosis, alpha-1-antitrypsin deficiency, viral hepatitis, auto-immune hepatitis, etc.);\n* Pharmacological treatment targeting obesity active or ended in the last 3 months;\n* Bariatric surgery;\n* Gastro-intestinal pathologies (GI cancers, IBD, etc.);\n* Capsulated probiotics consumption;\n* Antibiotic treatment in the last 3 months;\n* Pregnancy;\n* Cirrhosis diagnosis (hepatic decompensation).",{"count":214,"type":21},120,[56],"The goal of this clinical trial is to improve the treatment of hepatic steatosis associated with obesity with pharmacological and nutritionnal approaches. The main question it aims to answer is:\n\nDoes an individualized nutritionnal approach with a dietician combined with medication targeting obesity is the most efficient way to treat hepatic steatosis associated with obesity?\n\nParticipants will either participate in one of three groups:\n\n* Nutrition: Participant will only have a regular follow-up with a registered dietician;\n* Nutrition + Semaglutide: Participants will start a new medication targeting obesity and will have a regular follow-up with a registered dietician;\n* Semaglutide: Participants will start a new medication targeting obesity.",[218,219,154],"Metabolic Associated Fatty Liver Disease","Metabolic Associated-dysfunction Steatohepatitis (MASH)",[154,221,222,223,224,225,226,227,228],"Metabolic associated fatty liver disease","GLP-1 receptor analogs","Pharmacotherapy","Nutrition","Transient elastography","Semaglutide","Microbiome","Lipidomics","2025-01-07",{"date":231,"type":36},"2025-01-08",{"date":233,"type":21},"2025-01",{"date":235,"type":21},"2026-05",{"name":42,"class":43},{"id":238,"slug":239,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":243,"eligibilityCriteria":244,"healthyVolunteers":11,"sex":17,"minAge":245,"maxAge":246,"enrollmentInfo":247,"targetDuration":4,"studyType":54,"phases":249,"briefSummary":251,"conditions":252,"keywords":254,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":267},"100432650","phase-4-angiotensin-receptor-blockers-in-aortic-stenosis-100432650","NCT04913870","Angiotensin Receptor Blockers in Aortic Stenosis","Impact of Angiotensin Receptor Blockers in Aortic Stenosis - a Randomized Controlled Trial","ARBAS","Inclusion Criteria:\n\n* Mild to moderate aortic stenosis (peak aortic jet velocity ≥2.5 and \\\u003C4m\u002Fs)\n* Normal left ventricular ejection fraction (i.e. ≥50%)\n* Systolic blood pressure \\>110 mmHg\n* Diastolic blood pressure \\>70 mmHg\n\nExclusion Criteria:\n\n* More than mild aortic or mitral regurgitation, or mitral stenosis\n* Current use or documented indication for renin-angiotensin system medication or Aliskiren\n* Known allergy or intolerance to angiotensin II receptor blockers (ARBs)\n* Alzheimer, dementia or known non-compliant patient\n* Renal dysfunction (glomerular filtration rate \\\u003C30ml\u002Fmin\u002F1.73m2)\n* Chronic hyperkalemia\n* Diagnosed hepatic failure, cirrhosis, hepatitis or history of hepatic impairment\n* Newly diagnosed (\\\u003C2 months) or poorly controlled diabetes\n* Pre-existing obstructive coronary artery disease with CCS III-IV angina or recent myocardial infarction (\\\u003C3 months)\n* Pregnant or lactating women\n* Patients unable to read, understand or sign research consent","20 Years","99 Years",{"count":248,"type":21},144,[250],"PHASE4","This study is intended to investigate the effect of angiotensin receptor blockers (ARBs) on mild-to-moderate aortic stenosis.",[253,88],"Aortic Stenosis",[255,256,257,258],"Angiotensin II Receptor Blockers","Left ventricular remodeling","Valvular heart disease","Aortic stenosis","2024-12-18",{"date":261,"type":36},"2024-12-20",{"date":263,"type":36},"2020-02-01",{"date":265,"type":21},"2027-02",{"name":42,"class":43},2,""]